Evidence map›Paper›PMID 28387933›Full record

ReviewEpilepsia2017

WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?

Sergiusz Jozwiak, Albert Becker, Carlos Cepeda, Jerome Engel, Vadym Gnatkovsky, Gilles Huberfeld, Mehmet Kaya, Katja Kobow, Michele Simonato, Jeffrey A Loeb

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epilepsia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers.Journal of neuropathology and experimental neurology · 2020
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Sergiusz JozwiakDepartment of Child Neurology, Medical University of Warsaw, Warsaw, Poland.
Albert BeckerSection for Translational Epilepsy Research, Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
Carlos CepedaIDDRC, Semel Institute for Neuroscience & Human Behavior, University of California Los Angeles, Los Angeles, California, U.S.A.
Jerome EngelDepartments of Neurology, Neurobiology, and Psychiatry & Biobehavioral Sciences and the Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.
Vadym GnatkovskyUnit of Epilepsy and Experimental Neurophysiology, The Foundation of the Carlo Besta Neurological Institute, Milan, Italy.
Gilles HuberfeldAP-HP, Department of Neurophysiology, UPMC and The Pitié-Salpêtrière Hospital, Sorbonne and UPMC University, Paris, France.
Mehmet KayaDepartment of Physiology, Koc University School of Medicine, Istanbul, Turkey.
Katja KobowDepartment of Neuropathology, University Hospital Erlangen, Erlangen, Germany.
Michele SimonatoDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Jeffrey A LoebDepartment of Neurology and Rehabilitation, The University of Illinois at Chicago, Chicago, Illinois, U.S.A.
Délégation Paris 5 · FRFondazione IRCCS Istituto Neurologico Carlo Besta · ITKoç University · TRMedical University of Warsaw · PLUniversitätsklinikum Erlangen · DEUniversity of Bonn · DEUniversity of Ferrara · IT

Funding

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) Public Engagement CoreU54NS100064 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TOGA, ARTHUR W · 2017 to 2021
$21.7M
SYSTEMS PATHOPHYSIOLOGYP01NS002808 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRAGIN, ANATOL · 1985 to 2010
$13.5M
Early Randomized Surgical Epilepsy TrialU01NS042372 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE · 2002 to 2007
$9.8M
IN VIVO STUDIES OF THE EPILEPTIC HIPPOCAMPUSR01NS033310 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JEROME NONE ENGEL, Richard Staba · 1994 to 2026
$7.5M
In Vivo Studies of the Epileptic HippocampusRF1NS033310 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE, STABA, RICHARD · 2023 to 2023
$3.6M
IN VIVO STUDIES OF THE EPILEPTIC HIPPOCAMPUSR37NS033310 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE · 2004 to 2010
$3.2M
Activity-Dependent Gene Expression in Human EpilepsyR01NS045207 · NINDS · WAYNE STATE UNIVERSITY · PI LOEB, JEFFREY A · 2003 to 2010
$2.1M
The Epilepsy Bioinformatics Study (EpiBioS)P20NS080181 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE, HOVDA, DAVID A · 2012 to 2014
$1.7M
High Frequency Oscillation as a Biomarker in Childhood EpilepsyR01NS082649 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, JOYCE Y · 2013 to 2017
$1.7M
Electrical, Molecular and Clinical Correlates of Human Interictal SpikingR01NS058802 · NINDS · WAYNE STATE UNIVERSITY · PI LOEB, JEFFREY A · 2008 to 2012
$1.6M
MAPK Signaling in Neocortical EpilepsyR56NS083527 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LOEB, JEFFREY A · 2015 to 2015
$400k
NINDS NIH HHS P01 NS002808NINDS NIH HHS P20 NS080181NINDS NIH HHS R01 NS033310NINDS NIH HHS R01 NS045207NINDS NIH HHS R01 NS058802NINDS NIH HHS R01 NS082649NINDS NIH HHS R37 NS033310NINDS NIH HHS R56 NS083527NINDS NIH HHS RF1 NS033310NINDS NIH HHS U01 NS042372NINDS NIH HHS U54 NS100064
6 · The paper itself

Abstract

objectiveCurrent medications for patients with epilepsy work in only two of three patients. For those medications that do work, they only suppress seizures. They treat the symptoms, but do not modify the underlying disease, forcing patients to take these drugs with significant side effects, often for the rest of their lives. A major limitation in our ability to advance new therapeutics that permanently prevent, reduce the frequency of, or cure epilepsy comes from a lack of understanding of the disease coupled with a lack of reliable biomarkers that can predict who has or who will get epilepsy.

methodsThe main goal of this report is to present a number of approaches for identifying reliable biomarkers from observing patients with brain disorders that have a high probability of producing epilepsy.

resultsA given biomarker, or more likely a profile of biomarkers, will have both a quantity and a time course during epileptogenesis that can be used to predict who will get the disease, to confirm epilepsy as a diagnosis, to identify coexisting pathologies, and to monitor the course of treatments. SIGNIFICANCE: Additional studies in patients and animal models could identify common and clinically valuable biomarkers to successfully translate animal studies into new and effective clinical trials.

Indexed as

BiomarkersAnimalsAnticonvulsantsBrainDisease Models, AnimalEpilepsyHumansRisk FactorsTranslational Research, BiomedicalTreatment OutcomeAnticonvulsantsBiomarkersAnimal modelsElectroencephalographyEpileptogenesisHuman studiesMRI

Identifiers

PMID28387933
PMCPMC5806696
OpenAlexW2604874691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.